BridgeBio Pharma, Inc. Equity Securities, FV-NI, Unrealized Gain
BridgeBio Pharma, Inc. (BBIO) reported Equity Securities, FV-NI, Unrealized Gain of $68.54 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2022-02-25
- BridgeBio Pharma, Inc. equity securities, fv-ni, unrealized gain for fiscal 2021 was $68.54M.
| Period end | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|
| 2021-12-31 | $68.54M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |